A Dopamine D1-Like Receptor Agonist Ameliorates Traumatic Brain Injury Through its Immunosuppressive Effects - PubMed
6 hours ago
- #Traumatic Brain Injury
- #Dopamine Receptor Agonist
- #Neuroinflammation
- Traumatic brain injury (TBI) leads to progressive nervous tissue degeneration due to secondary neuroinflammatory reactions.
- Dopamine D1-like receptor agonist SKF-81297 (SKF) was studied for its potential to ameliorate TBI in a rat model.
- SKF reduced brain tissue loss, improved mobility, and alleviated cognitive dysfunction two months post-TBI.
- SKF suppressed IL-1β and TNFα expression in brain tissue, reducing oxidative injury at 24 hours post-TBI.
- SKF decreased energy metabolism in microglia, macrophages, and neutrophils in TBI-affected brain areas.
- SKF prevented LPS-induced NFκB translocation in primary cultured microglia, indicating anti-inflammatory effects.
- Clenbuterol (CLB), an adrenergic β2 receptor agonist, showed similar ameliorative effects by suppressing neuroinflammation.
- The study suggests SKF's anti-inflammatory effects are mediated via cAMP increase and NFκB pathway suppression.